Cargando…

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer

Background: Treating cancer according to its molecular alterations (i.e., targeted treatment, TT) is the goal of precision medicine tumor boards (PTBs). Their clinical applicability has been evaluated for ovarian cancer patients in this analysis. Methods: All consecutive ovarian cancer patients disc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139570/ https://www.ncbi.nlm.nih.gov/pubmed/32120793 http://dx.doi.org/10.3390/cancers12030548

Ejemplares similares

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
por: Grech, Christina T., et al.
Publicado: (2022)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
por: Oberndorfer, Felicitas, et al.
Publicado: (2021)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2013)

Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2015)

The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer
por: Bartl, Thomas, et al.
Publicado: (2020)

Defining Models to Classify between Benign and Malignant Adnexal Masses Using Routine Laboratory Parameters
por: Reiser, Elisabeth, et al.
Publicado: (2022)

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy
por: Poetsch, Nina, et al.
Publicado: (2019)

Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature
por: Mailath-Pokorny, Mariella, et al.
Publicado: (2016)

Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy
por: Sturdza, Alina, et al.
Publicado: (2017)

The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate
por: Bekos, Christine, et al.
Publicado: (2022)

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma
por: Schwameis, Richard, et al.
Publicado: (2015)

NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach
por: Bekos, Christine, et al.
Publicado: (2019)

Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score
por: Seebacher, Veronika, et al.
Publicado: (2018)

Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2016)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma
por: Schwameis, Richard, et al.
Publicado: (2016)

Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen
por: Seebacher, Veronika, et al.
Publicado: (2017)

Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Prognostic value of serum creatine level in patients with vulvar cancer
por: Schwameis, Richard, et al.
Publicado: (2019)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery
por: Bekos, Christine, et al.
Publicado: (2019)

Impact of frailty on the management of patients with gynecological cancer aged 80 years and older
por: Reiser, Elisabeth, et al.
Publicado: (2020)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial
por: Seebacher, V, et al.
Publicado: (2013)

Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
por: Grimm, C, et al.
Publicado: (2013)

Reply: Lymph node density as a surrogate marker for positive lymph nodes
por: Polterauer, S, et al.
Publicado: (2011)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
por: Hofstetter, Gerda, et al.
Publicado: (2022)

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
por: Lamm, Wolfgang, et al.
Publicado: (2014)

Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis
por: Bekos, Christine, et al.
Publicado: (2018)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report
por: Paspalj, V., et al.
Publicado: (2021)

A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial
por: Grimm, Christoph, et al.
Publicado: (2014)

Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?
por: Sukhbaatar, Nyamdelger, et al.
Publicado: (2017)

A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types
por: Pils, Dietmar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_379sbge39hnoglhvhpsdnod7nd